Explore 3 Stock Ideas & Industry Insights Download Free Report

Nascent Biotech Inc

Company price
0.0004 USD 0.00(0%)
Last update at 2026-11-17T21:00:00Z
VOLUME
15000
Market Cap
33.76M

Momentum Score

…

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.03
Low
0.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Nascent Biotech Inc is an OTCQB-listed biotechnology company with limited public disclosures about its operations and pipeline. Its long-term growth may depend on successful R&D, regulatory approvals and potential partnerships or commercialization of any clinical assets. Investors may find upside if clinical milestones are achieved and financing is secured, but outcomes are uncertain.
The most important investment risk is limited disclosure and early-stage status, which increase execution, regulatory and financing risk and often coincide with low trading liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
1.00M
Debt / Equity
-
ROE
-
Net Debt
0.22M
ROCE
165.12%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -2.80M -0.47M -0.96M -4.00M -1.37M
Minority interest - - - - 0.00M
Net income -2.80M -0.47M -0.96M -4.00M -1.37M
Selling general administrative 1.49M 0.93M 1.83M 3.15M 1.11M
Gross profit - - 0.75M - 0.00M
Ebit - -0.46M -0.96M -3.45M -1.37M
Ebitda -1.08M -0.13M -0.62M -3.92M -1.37M
Non operating income net other - - 0.44M - 0.00M
Operating income -2.14M -0.46M -1.40M -3.45M -1.37M
Other operating expenses - - - - 0.00M
Interest expense 1.72M 0.34M 0.34M 0.09M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M -
Interest income 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -1.73M -0.49M -0.36M -0.09M 0.00M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense - - - - 0.00M
Total revenue 0.00M 1.00M 0.75M 0.00M 0.00M
Total operating expenses 2.14M 1.46M 2.15M 3.45M 1.37M
Cost of revenue - - - - 0.00M
Total other income expense net 1.08M 0.47M 0.80M -0.47M 0.00M
Discontinued operations - - - - 0.00M
Net income from continuing ops -2.80M -0.47M -0.96M -4.00M -1.37M
Net income applicable to common shares - -0.47M -0.96M -4.00M -1.37M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 0.26M 0.11M 0.75M 0.00M 0.13M
Intangible assets - - - - 0.00M
Other current assets - - - - 0.00M
Total liab 1.55M 0.78M 1.22M 2.88M 0.61M
Total stockholder equity -1.30M -0.67M -0.47M -2.88M -0.48M
Deferred long term liab - - - - 0.00M
Other current liab 0.66M - 0.30M 0.60M 0.09M
Common stock - 0.11M 0.10M 0.04M 0.03M
Capital stock 0.13M 0.11M 0.10M 0.04M 0.03M
Retained earnings -21.62M -18.82M -18.35M -16.84M -12.83M
Other liab - - - - 0.00M
Good will - - - - 0.00M
Other assets - - - - 0.00M
Cash 0.17M 0.09M 0.00M 0.00M 0.13M
Total current liabilities 1.55M 0.78M 1.22M 2.88M 0.61M
Net debt 0.22M - 0.16M 0.14M -
Short term debt - - 0.46M - 0.00M
Short long term debt 0.39M - 0.16M 0.14M 0.00M
Other stockholder equity - - - - 0.00M
Property plant equipment - - - - 0.00M
Total current assets 0.26M 0.11M 0.75M 0.00M 0.13M
Long term investments - - - - 0.00M
Net tangible assets - -0.67M -0.47M -2.88M -0.48M
Short term investments - - - - 0.00M
Net receivables - 0.00M 0.75M - -
Long term debt - - - - 0.00M
Inventory - - - - 0.00M
Accounts payable 0.50M 0.78M 0.76M 0.85M 0.53M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income - - - - 0.00M
Additional paid in capital - - - - 0.00M
Common stock total equity - - 0.10M - 0.00M
Preferred stock total equity - - 0.00M - 0.00M
Retained earnings total equity - - -18.35M - 0.00M
Treasury stock - - - - 0.00M
Accumulated amortization - - - - 0.00M
Non currrent assets other - - - - 0.00M
Deferred long term asset charges - - - - 0.00M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Capital lease obligations - - - - 0.00M
Long term debt total - - - - 0.00M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments - - - - 0.00M
Change to liabilities - 0.17M 0.65M 0.33M 0.32M
Total cashflows from investing activities - - - - 0.00M
Net borrowings - -0.32M 0.34M 0.20M 0.20M
Total cash from financing activities 1.86M -0.32M 0.98M 0.43M 0.73M
Change to operating activities - -0.01M 0.42M 1.49M 0.09M
Net income -2.80M -0.47M -0.96M -4.00M -1.37M
Change in cash 0.08M 0.09M -0.00M -0.13M 0.01M
Begin period cash flow 0.09M 0.00M 0.00M 0.13M 0.12M
End period cash flow 0.17M 0.09M 0.00M 0.00M 0.13M
Total cash from operating activities -1.79M 0.41M -0.99M -0.55M -0.71M
Issuance of capital stock - 0.00M 0.64M 0.23M 0.64M
Depreciation - - - - 0.00M
Other cashflows from investing activities - - - - 0.00M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables 0.00M 0.75M -0.75M -0.75M -0.75M
Sale purchase of stock - - 0.64M - 0.00M
Other cashflows from financing activities - - - - 0.00M
Change to netincome - -0.35M 0.79M 1.57M 0.25M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change receivables - - - - 0.00M
Cash flows other operating - - -1.17M - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - -0.00M - 0.00M
Change in working capital -0.32M 0.91M -0.10M 1.82M 0.41M
Stock based compensation 0.76M 0.12M 0.79M 1.10M 0.21M
Other non cash items 1.63M 0.33M 0.09M 0.06M 0.04M
Free cash flow -1.79M 0.41M -0.99M -0.55M -0.71M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NBIO
Nascent Biotech Inc
-
-%
0.00 - - 8.93 6.91 21.83 -24.97
NVO
Novo Nordisk A/S
-1.05
2.58%
39.65 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
3.46
0.65%
537.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-11.46
1.20%
946.29 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Nascent Biotech Inc

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

623 17th Street, Vero Beach, FL, United States, 32960

612 961 5656

Name Title Year Born
Mr. Sean Carrick Pres, CEO, Sec. & Director 1968
Mr. Lowell Holden CFO, Chief Accounting Officer & Director 1943
Dr. Mark C. Glassy Founder & Chairman of Scientific Advisory Board 1952
Dr. Navpaul Singh M.D. Chief Medical Consultant NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…